Novartis Benefits From Lack of Generic Challenge
April 24 (Bloomberg) -- Bloomberg's Jonathan Ferro reports that Novartis AG saw first-quarter profit rise 7 percent as a competitor's generic version of the company’s second-best-selling medicine failed to reach the market. He speaks on Bloomberg Television's "On The Move."
Most Recent Videos
Full Show: Bloomberg Technology (03/27)
24:44 - Guests include: Oppenheimer's Jason Helfstein, Siemens CTO Roland Busch, Alston & Bird's Michael Zweiback and Morgan Stanley's Adam Jonas. (Source: Bloomberg)